Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00148993 |
Recruitment Status
:
Withdrawn
(PI (Prof. Slavin) not longer work at Hadassah)
First Posted
: September 8, 2005
Last Update Posted
: April 8, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Solid Tumors | Biological: Tumor Cell Vaccine | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors |
Study Start Date : | July 1998 |
Estimated Study Completion Date : | July 2005 |
- Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.
- Investigate the feasibility of immune responses against cancer cells by combining allogeneic TCV with indomethacin, cimetidine, tetanus and rIL-2.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with measurable metastatic disease or disease resistant to chemotherapy or with minimal residual disease at high risk to relapse.
Exclusion Criteria:
- Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents or immunosuppressive agents which may interfere with optimal immune response.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00148993
Israel | |
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI) | |
Tel Aviv, Israel, 64239 |
Principal Investigator: | shimon slavin, MD | The International Center for Cell Therapy & Cancer Immunotherapy (CTCI) |
Responsible Party: | Shimon Slavin MD, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI) |
ClinicalTrials.gov Identifier: | NCT00148993 History of Changes |
Other Study ID Numbers: |
100798-HMO-CTIL |
First Posted: | September 8, 2005 Key Record Dates |
Last Update Posted: | April 8, 2011 |
Last Verified: | July 2005 |
Keywords provided by Hadassah Medical Organization:
Tumor cell vaccine |
Additional relevant MeSH terms:
Vaccines Immunologic Factors Physiological Effects of Drugs |